SCHEMBL20920127

SCHEMBL20920127

Cc1cc(-c2nn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c3cc([N+](=O)[O-])c([N+](=O)[O-])cc23)ccn1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
MAPK1 P28482 5/20 0.34
MAPT P10636 8/20 0.34
NPSR1 Q6W5P4 3/20 0.34
LMNA P02545 2/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
HTR6 P50406 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
KDM4E B2RXH2 1/20 0.33
PSMD14 O00487 1/20 0.33
APAF1 O14727 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16213478 0.92 L3MBTL1 (0.38) L3MBTL1MAPK1MAPTNPSR1LMNA
SCHEMBL16213259 0.90 L3MBTL1 (0.34) L3MBTL1MAPK1MAPTNPSR1LMNA
SCHEMBL19567956 0.90 MAPK1 (0.35) L3MBTL1MAPK1MAPTNPSR1LMNA
SCHEMBL16213601 0.90 L3MBTL1 (0.34) L3MBTL1MAPK1MAPTNPSR1LMNA
SCHEMBL16213206 0.88 MAPK1 (0.34) L3MBTL1MAPK1MAPTLMNAKMT2A
SCHEMBL16224969 0.87 MAPK1 (0.33) L3MBTL1MAPK1MAPTLMNAKMT2A
SCHEMBL17555399 0.86 MAPT (0.42) L3MBTL1MAPTNPSR1LMNAGAA
SCHEMBL17555398 0.86 MAPT (0.42) L3MBTL1MAPTNPSR1LMNAGAA
SCHEMBL16213443 0.86 CTSB (0.43) L3MBTL1MAPK1MAPTLMNAHTT
SCHEMBL17555400 0.86 MAPT (0.42) L3MBTL1MAPTNPSR1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110546150-B Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof 江苏豪森药业集团有限公司 2021-12-21 CN disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
CN-110546150-A Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD 2019-12-06 CN disclosed
WO-2019076336-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 L3MBTL1 3754/4885MAPK1 1/4885MAPT 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.